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Abstract
Purpose Breast cancer tumour-infiltrating lymphocytes associate with clinico-pathological factors, including survival, 
although the literature includes many conflicting findings. Our aim was to assess these associations for key lymphocyte 
subtypes and in different tumour compartments, to determine whether these provide differential correlations and could, 
therefore, explain published inconsistencies. Uniquely, we also examine whether infiltrating levels merely reflect systemic 
lymphocyte levels or whether local factors are predominant in recruitment.
Methods Immunohistochemistry was used to detect tumour-infiltrating CD20+ (B), CD4+ (helper T), CD8+ (cytotoxic T) 
and FoxP3+ (regulatory T) cells in breast cancers from 62 patients, with quantification in tumour stroma, tumour cell nests, 
and tumour margins. Levels were analysed with respect to clinico-pathological characteristics and matched circulating levels 
(determined by flow-cytometry).
Results CD4+ lymphocytes were the most prevalent subtype in tumour stroma and at tumour edge and CD8+ lymphocytes 
were most prevalent in tumour nests; FoxP3+ lymphocytes were rarest in all compartments. High grade or hormone recep-
tor negative tumours generally had significantly increased lymphocytes, especially in tumour stroma. Only intra-tumoural 
levels of CD8+ lymphocytes correlated significantly with matched circulating levels (p < 0.03), suggesting that recruitment 
is mainly unrelated to systemic activity. High levels of stromal CD4+ and CD20+ cells associated with improved survival 
in hormone receptor negative cases (p < 0.04), while tumour nest CD8+ and FoxP3+ cells associated with poor survival in 
hormone receptor positives (p < 0.005).
Conclusions Lymphocyte subtype and location define differential impacts on tumour biology, therefore, roles of tumour-
infiltrating lymphocytes will only be unravelled through thorough analyses that take this into account.
Keywords Tumour-infiltrating lymphocytes · TILs · Breast cancer · Estrogen receptor · Circulating lymphocytes
Introduction
Tumour-infiltrating lymphocytes (TILs) are influential 
components of the tumour microenvironment and impli-
cations of their accumulation in breast cancers have been 
evaluated extensively [1, 2]. Extent of lymphocytic infil-
tration has been found to be associated with a variety of 
prognostic factors [3, 4], outcomes [5, 6] and, in some 
cases, outcomes after specific therapies [6, 7]. Despite this 
wealth of published data, key reproducible findings remain 
elusive, in part due to the range of methodologies used 
and variety of cohorts studied. In terms of methodologies, 
TILs were identified in many studies based on morphology 
using haematoxylin and eosin stained tissue, and indeed 
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s1054 9-020-05757 -5) contains 
supplementary material, which is available to authorized users.
 * Thomas A. Hughes 
 t.hughes@leeds.ac.uk
1 School of Medicine, University of Leeds, Leeds, UK
2 Department of Breast Surgery, Bolton Hospital NHS 
Foundation Trust, Bolton, UK
3 Department of Histopathology, St. James’s University 
Hospital, Leeds, UK
4 Department of Breast Surgery, Leeds Teaching Hospitals 
NHS Trust, Leeds, UK
5 Department of Transplant Immunology, Leeds Teaching 
Hospitals NHS Trust, Leeds, UK
50 Breast Cancer Research and Treatment (2020) 183:49–59
1 3
this was the recommendation by the International TILs 
Working Group [8]. However, this does not allow sepa-
rate quantification of distinct TIL subsets, such as B and 
T cells, that may have differential recruitment to tumours 
and differential associations with prognosis [9]; the lack 
of this distinction is a potential cause of some conflicting 
findings in the literature. Accordingly, there is a growing 
literature describing specific TIL subtypes, using immuno-
histochemistry for detection of individual subtype-specific 
markers [10, 11], or recently multiplexed simultaneous 
imaging of subtypes [12]. A further difficulty is variation 
in methods for quantification of TILs and their locations. 
Some authors have quantified in descriptive terms only, 
such as defining infiltration as mild, moderate or heavy 
[13, 14], while others have assessed percentages of tissue 
area occupied by TILs [5, 6], or have counted individual 
cells [3, 10]. In terms of tissue regions, some have made 
no distinction between different tumour areas [3, 6], while 
others have limited their analyses to single regions, most 
commonly tumour stroma [4, 5, 7] for which quantifica-
tion methods have been mainly standardised [8], or have 
quantified in a number of different regions separately [10, 
11], for example in tumour stroma, closely associated with 
tumour cells, or adjacent to the tumour margin, although 
analysis of all these regions remains exceedingly rare.
The result of these differing methodologies is that sum-
marising overall conclusions from the field is challenging, 
although reviews have been published [15, 16]. Some gen-
eralizable themes are: (1) There are typically more TILs 
in tumours showing markers of poor prognosis; (2) Higher 
levels of TILs are associated with better responses to neoad-
juvant chemotherapy; (3) Different subclasses of TILs, such 
as cytotoxic T, helper T, or regulatory T cells, have different 
relationships with outcomes.
Here, we have taken a thorough approach of quantifying 
the presence, relationships between, and prognostic impor-
tance of four different subclasses of TILs (cytotoxic T, helper 
T, regulatory T, and B cells) in three separate tumoural com-
partments in a breast cancer cohort that we have character-
ised previously. In addition, uniquely, we have assessed how 
these levels correlate with the matched circulating levels of 
these cells, to infer whether TILs recruitment is tumour-
driven independently of systemic levels – and if so for which 
TIL subtypes and in which tumoural compartments.
Methods and materials
Patient selection, ethics, clinical samples/data
Patient selection and recruitment has previously been 
described [17]. In brief, we recruited patients with diag-
noses of operable primary breast cancer and scheduled 
to receive chemotherapy at Leeds Teaching Hospitals 
NHS Trust (LTHT) between June 2011 and January 2012. 
Written, informed consent was taken. Exclusion criteria 
included age > 75 years, long-term steroids/immunosup-
pressive drug use, previous breast cancer, and previous 
chemotherapy within 10 years. Ethical approval for patient 
recruitment, data collection, and subsequent analyses was 
obtained from Leeds East REC (references 06/Q1206/217 
and 06/Q1206/180). Data regarding circulating lympho-
cytes in these patients has already been published [17]; 
circulating lymphocytes data used here are the pre-chem-
otherapy values, which were assessed at the closest time-
points to the point of tissue sampling (biopsy or resection 
as appropriate). 62 patients from this previous study have 
been included in this new work, based on tissue availabil-
ity; clinico-pathological data for these patients are shown 
in Table 1. Survival time was defined as time from diag-
nosis to death from cancer or to last alive follow up. Data 
are reported in accordance with REMARK [18].
Immunohistochemistry (IHC)
Archival tumour blocks were retrieved from the LTHT 
pathology department: pre-treatment diagnostic biopsies 
for cases treated with neoadjuvant chemotherapy (n = 7), 
surgical resections for the remainder. Hormone and HER2 
status of the neoadjuvant cases are shown in Table S1. 
5 μm sections were taken onto SuperFrost plus slides 
(Menzel-Glaser; Braunschweig, Germany). Sections were 
dewaxed (xylene) and rehydrated (ethanol) before washing 
in running tap water. Antigen retrieval was performed in 
10 mM citric buffer (pH 6.0) heated by microwave (full 
power) for 20 min. Slides were blocked in 3% hydrogen 
peroxide for 15 min followed by washes in tap water and 
Tris-Buffered Saline (TBS). Primary antibodies (Dako 
[Gostrup, Denmark] unless stated otherwise) were used 
in antibody diluent reagent (Invitrogen; Paisley, UK) as 
follows: anti-CD8 (clone C8/144B; 1:800 dilution; incuba-
tion overnight 4 °C), anti-CD4 (4B12; 1:200; 1 h 37 °C), 
anti-CD20 (L26; 1:400; 1 h 37 °C), anti-FoxP3 (236A/
E7; Abcam [Cambridge, UK]; 1:400; overnight 4 °C). 
Slides were washed × 3 in TBS, and IHC was completed 
using anti-mouse Envision reagents (Dako; Gostrup, 
Denmark) following the manufacturer’s protocols. Slides 
were washed in running tap water (2 min), stained with 
Mayer’s haematoxylin (30 s), and then washed in running 
water (1 min), Scott’s water (1 min), and running water 
(rinse). Sections were dehydrated in ethanol (3 × 1 min) 
and xylene (3 × 5 min) before being mounted under cov-
erslips in DePeX (VWR; Radnor, USA).
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Scoring of IHC staining
Slides were digitally scanned using ScanScopeXT at 
20 × and were manually scored using Webscope (both 
Aperio; Vista, CA, USA). Scoring was performed in accord-
ance with guidelines from the International TILs Work-
ing Group [8], applying these to IHC stains. Infiltration 
was quantified in three separate compartments: (1) intra-
tumoural within tumour stroma; (2) intra-tumoural within 
tumour cell nests; (3) at tumour margin. Scoring protocols 
were designed in consultation with a consultant breast histo-
pathologist (ETV). For scoring, entire slides were first exam-
ined at low magnification to assess broad distributions of 
tumour cells and TILs. 3 areas per resection or 2 for biopsies 
were then selected at ×10 magnification. The criteria used 
for selecting these areas included: presence of tumour cells, 
stroma and TILs, and lack of obvious staining artefacts or 
large areas of tissue loss. When TIL distribution was het-
erogeneous, areas with very high or low TILs were avoided. 
Selected areas were digitally marked at ×10 magnification 
using the Webscope pen tool, and marked areas were scored 
at ×20 magnification for TILs within the tumour nests and 
TILs in the tumour stromal areas. TILs within the tumour 
nests were defined as lymphocytes visually touching tumour 
cells, or within solid blocks of tumour cells without other 
visible stromal elements. These were quantified by counting 
the entire number of stained TILs and of tumour cells within 
the selected regions, and this was expressed as a continu-
ous ratio of TILs to tumour cells (i.e. 0.1 indicates 1 TIL 
to 10 tumour cells). Stromal lymphocytes were assessed 
by estimating proportions of the stromal area occupied 
by lymphocytes and were expressed as percentages; these 
were estimated in increments of 5%, except when below 
5% where individual integers were used. For each of these 
measures, means of the values for the multiple regions were 
taken as the values for each case. Finally, the tumour edge 
was located, when present on the slide, and TILs within this 
region was graded as mild, moderate or heavy infiltrate; edge 
was not scored on diagnostic biopsies from cases treated 
with neoadjuvant chemotherapy. Figures S1 and S2 contains 
representative images illustrating these scoring methods. All 
slides were scored by RV, while 10% of the slides for each 
antibody were additionally scored independently by breast 
histopathologist ETV, to allow statistical assessment of scor-
ing reproducibility; scorers were blinded to histopathology 
data concerning the cases while scoring. Scatter plots of the 
independent scores are shown in Fig. S3, demonstrating a 
very high degree of concordance (Spearman’s correlation 
coefficients > 0.98, p < 0.001).
Statistical analyses
Data were analysed using SPSSv22 (SPSS; Chicago, 
USA). Relationships were considered significant if p val-
ues were ≤ 0.05. For IHC analyses, association between two 
independent scorers was assessed using correlation coeffi-
cients. Wilcoxon’s signed rank test or Friedman’s two-way 
Analysis of Variance by Ranks (ANOVA) was used to assess 
differences in TIL distributions. Analyses involving the edge 
quantification of mild, moderate, and heavy were performed 
where appropriate by replacing these classes with numerical 
scores of 1, 2 and 3 respectively when appropriate. Correla-
tion between different TIL locations, and with clinical and 
pathological factors were assessed using Spearman’s corre-
lation coefficients. Survival analyses were performed using 
Kaplan–Meier plots with log rank statistics.
Table 1  Clinico-pathological details of the cohort (n = 62)
EC epirubicin/cyclophosphamide, FEC fluorouracil/epirubicin/cyclo-
phosphamide, GCSF granulocyte colony-stimulating factor, DOCET 
docetaxel
Characteristic N (%)
Age
 20–40 years 4 (6.5%)
 41–60 years 38 (61.2%)
 61–75 years 20 (32.3%)
Tumour grade
 Grade 1 0 (0%)
 Grade 2 25 (40.3%)
 Grade 3 37 (59.7%)
Tumour size
 < 2 cm 34 (54.8%)
 2–5 cm 26 (42.0%)
 > 5 cm 2 (3.2%)
Nodal metastasis
 No 30 (48.4%)
 Yes 32 (51.6%)
Hormone receptor status
 ER/PR positive 35 (56.4%)
 ER/PR negative 27 (44.0%)
Her2 status
 Negative 51 (82.2%)
 Positive 11 (17.7%)
Chemotherapy type
 Neoadjuvant 7 (11.3%)
 Adjuvant 55 (88.7%)
Chemotherapy regimen
 EC/FEC 29 (46.8%)
 EC+ GCSF/EC+ DOCET+ GCSF 31 (50.0%)
 Paclitaxel/others 2 (3.2%)
Radiotherapy
 No 10 (16.1%)
 Yes 52 (83.9%)
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Results
Building on our previous analyses of circulating levels of 
lymphocytes in primary breast cancer patients [17], we have 
now examined relative numbers and locations within breast 
cancer tissues of lymphocytes showing positivity for mark-
ers CD20 (B cells), CD4 (helper T cells), CD8 (cytotoxic T 
cells) and FoxP3 (regulatory T cells) in tumours from the 
same patients (n = 62). Clinico-pathological characteristics 
of patients included are listed (Table 1), while representative 
staining of lymphocytes is shown in Fig. 1. Lymphocytes 
were analysed in resection tissues for the majority of cases 
(n = 55), or using diagnostic biopsies for the cases treated 
with neoadjuvant chemotherapy (n = 7).
Lymphocyte subtypes accumulate differentially 
in specific tumour locations
The four key lymphocyte subtypes above were quantified 
in three separate locations within the tumour microenvi-
ronment: in regions of tumour stroma, closely associated 
with tumour cells (in the tumour nests), and at the tumour 
edge (Fig. 2). Infiltration was often highly variable between 
different cancers; for example, the most extreme variation 
was seen with stromal CD4+ lymphocytes occupying from 
0.5% to 80% of tumour stromal area. Within each location, 
distributions of scores for the four subtypes frequently dif-
fered significantly, demonstrating that the subtypes infiltrate 
tumours to different degrees. For example, CD20+ lympho-
cytes were significantly rarer than CD4+ lymphocytes in 
both stroma and tumour nests (p < 0.05). Interestingly, the 
most prevalent subtypes differed between locations, with 
CD4+ lymphocytes being the most prevalent in tumour 
stroma and at the tumour edge, while CD8+ lymphocytes 
Fig. 1  Representative images of immunohistochemical staining (brown) of markers CD20 (for B lymphocytes), CD4 (helper T lymphocytes), 
CD8 (cytotoxic T lymphocytes) and FoxP3+ (regulatory T lymphocytes) showing positivity within tumour nests
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were the most prevalent in tumour nests. FoxP3+ lympho-
cytes were the rarest in all locations, demonstrating uni-
formly low levels in tumour stroma, more variable levels 
in the tumour nests levels although still relatively low, and 
predominantly only mild infiltration at the tumour edge. 
In order to support the validity of combining scores from 
resection samples with some from diagnostic biopsies, we 
have compared the distributions of stromal and tumour-nest 
scores from the combined cohort (n = 62) with those from 
only the resection samples (n = 55) (Table S2); no significant 
differences were found.
Infiltration with lymphocyte subtypes positively 
correlates within and across tumour compartments, 
except T cell infiltration of tumour edge
Next, we tested whether infiltration with one lymphocyte 
subtype in a compartment was associated with infiltration 
with the other subtypes in the same compartment. The 
degree of infiltration of each subtype was significantly posi-
tively associated with infiltration of all other subtypes, and 
this was the case in all three compartments; Spearman’s cor-
relation coefficients from 0.47 to 0.83 (p < 0.001) (Table S3). 
We also examined whether infiltration with a particular sub-
type in one compartment was associated with infiltration of 
this subtype into the other compartments (Table 2). Levels 
of CD20+ lymphocytes in each of the three compartments 
were significantly positively associated with each other, 
demonstrating that for this subtype the compartments are 
not strongly independent. For CD4+, CD8+ and FoxP3+ 
cells, there were also significant correlations between levels 
of infiltration in tumour stroma and tumour nests, but by 
contrast neither of these compartments showed significant 
correlations with infiltration at the tumour edge, suggesting 
that factors governing T cell infiltration differ between the 
intra-tumoural spaces and the tumour edge.
High grade or hormone receptor negative tumours 
have increased lymphocyte infiltrates, especially 
in tumour stroma
TIL levels have previously been found to vary according to 
various prognostic features, including grade and receptor 
status [19–21]. We next tested whether this was the case 
for our cohort using the clinical data associated with cases 
(Table 1), with particular focus on whether correlations dif-
fered between separate tumour compartments. Our cohort 
did not contain any grade 1 tumours, as is typical for patients 
Fig. 2  Tumour infiltrating lymphocytes differ in subclass in differ-
ent intra-tumoural locations. Tumour sections from a cohort of 62 
primary breast cancer patients were stained for lymphocyte markers 
CD20, CD4, CD8 or FoxP3. Tumour infiltrating lymphocytes (TILs) 
were quantified in three separate intra-tumoural locations: a within 
regions of tumour stroma (quantified as % of stromal area occupied 
by lymphocytes staining positive for marker under test); b within 
nests of tumour cells (quantified as the ratio of the number of lym-
phocytes staining positive for marker under test to the number of can-
cer cells); c tumour edge (classes as showing mild [light grey], mod-
erate [mid grey] or heavy infiltration [dark grey] with lymphocytes 
staining positive for marker under test. Data in a and b are shown in 
box and whisker plots with mean value (horizontal bar), 50% of the 
data (box), interquartile range (whiskers) and outliers (circles). Data 
in c are shown as the proportion of the entire cohort showing each 
degree of infiltration. * indicates p < 0.05 by Wilcoxon’s signed rank 
tests
Table 2  Correlation between the different tumour compartments for 
each lymphocyte subtype
Spearman’s correlation tests were performed to assess associations 
between levels of lymphocytes in the tumour stroma, within the 
tumour nests and at tumour edge. Correlation coefficients are shown 
when there was a significant correlation with p values in brackets
ns not significant
Stromal % vs 
tumour nest ratio
Stromal % vs tumour 
edge
Tumour nest 
ratio vs tumour 
edge
CD20 0.593 (p < 0.001) 0.304 (p = 0.017) 0.338 (p = 0.008)
CD4 0.694 (p < 0.001) ns ns
CD8 0.571 (p < 0.001) ns ns
FoxP3 0.470 (p < 0.001) ns ns
54 Breast Cancer Research and Treatment (2020) 183:49–59
1 3
scheduled to receive cytotoxic chemotherapy, therefore we 
compared TIL infiltration between grade 2 and grade 3 
tumours (Fig. 3a). Grade 3 tumours showed significantly 
greater infiltration of CD20+, CD8+ and FoxP3+ lympho-
cytes within the stromal compartment (all p < 0.05), while 
this was significant in the tumour nests only for FoxP3+ 
lymphocytes (p = 0.008). All four lymphocyte classes 
showed increased infiltration at the tumour edge in grade 3 
tumours, as indicated by consistently increased proportions 
showing heavy infiltration. Furthermore, infiltrates were also 
significantly greater in ER/PR negative tumours compared 
to ER/PR positive (Fig. 3b). For example, CD20+, CD4+ 
and FoxP3+ lymphocytes were all significantly higher in the 
stromal compartment of the ER/PR negative tumours (all 
p < 0.03), and all four subtypes were similarly more preva-
lent at the tumour edge. By contrast, however, no subtypes 
differed significantly in the tumour nests (Fig. 3b). The other 
clinically relevant prognostic factors tumour size and nodal 
status did not show significant correlations with lymphocyte 
distribution. We concluded that poor prognostic factors that 
are direct cellular characteristics of the primary tumour are 
associated with increased TILs, and—surprisingly—that 
these associations are more prominent within tumour 
stroma and tumour edge as compared to the tumour nests 
themselves.
Levels of intra‑tumoural CD8+ lymphocytes 
correlate with levels of circulating CD8+ 
lymphocytes
Taking advantage of the fact that we also have available the 
matched circulating levels of different lymphocyte subtypes 
from a previous study [17], we tested to what extent TIL lev-
els reflect systemic levels. Correlation tests were performed 
between the different compartments of CD20+, CD4+ and 
CD8+ TILs and the matched numbers of circulating CD20+, 
CD4+ and CD8+ cells. FoxP3+ TILs were compared with 
circulating levels of CD25+ FoxP3+, which is a more spe-
cific definition of regulatory T cells used for circulating cells 
as it is possible with flow-cytometric assessment. The only 
significant correlations were positive correlations between 
circulating CD8+ lymphocyte and CD8+ TILs levels in both 
the tumour stroma and tumour nests (r = 0.313 p = 0.024 
and r = 0.375 p = 0.006, respectively). Interestingly, the 
Fig. 3  Tumour infiltrating lymphocytes differ based on tumour grade 
and hormone receptor status. Levels of lymphocyte staining for CD20 
(20), CD4 (4), CD8 (8) or FoxP3 (P3) in either tumour stroma (left), 
tumour cell nests (middle), or tumour edge (right) were compared 
between tumours of grade 2 vs grade 3 (a) or ER/PR negative vs posi-
tive (b). * indicates p < 0.05 by Wilcoxon’s signed rank tests, except 
in the case of tumour edge where it indicates p < 0.05 by Friedman’s 
tests nm
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tumour nest correlation was stronger in the ER/PR-negative 
tumours (r = 0.466, p = 0.033), but not significant in the ER/
PR positive group. We concluded that levels of only CD8+ 
TILs correlated with matched circulating levels, suggesting 
that overall systemic lymphocyte levels are relatively weak 
influences on recruitment of most TILs, with local tumoural 
influences predominating.
High levels of stromal CD4+ and CD20+ cells 
associate with improved survival only in ER/PR 
negative cases, while tumour nest CD8+ and FoxP3+ 
cells associate with poor survival only in ER/PR 
positive cases
Published data demonstrate that TIL levels correlate with 
survival of breast cancer patients [15, 16]. However, few 
studies have examined the relevance of different intra-
tumoural locations for TIL subtypes, or in different cancer 
subgroups such as hormone receptor positive and negative. 
Kaplan–Meier survival analyses were used to compare sur-
vival in patients with either relatively high or low levels of 
each TIL subtype in each location. Receiver Operator Curve 
(ROC) analyses were used to define objective cut off values 
to dichotomise the cohort into these high and low groups 
for tumour nest TILs and tumour stroma TILs, based on 
sensitivity and specificity for prediction of cancer-specific 
death; cut off values are shown in Table S4.
Using the whole cohort, the only significant relationship 
with survival was for stromal CD4+ lymphocytes, with 
high infiltration significantly associated with improved sur-
vival; these patients had mortality of 4% as compared to 
36% in those with low infiltration at the median follow-up 
of 50 months (p = 0.015; Fig. 4a left panel). Interestingly, 
this correlation was based entirely on significance in ER/
PR negative patients (p = 0.039), whereas there was no sig-
nificant relationship in the ER/PR positive group (Fig. 4a 
middle and right panels). Similarly, high stromal CD20+ 
infiltration was also significantly associated with improved 
survival in ER/PR negative patients (p = 0.034), but not in 
the ER/PR positive group (Fig. 4b). Stromal CD8+ and 
FoxP3+ lymphocytes did not significantly correlate with 
outcomes. By contrast, in the tumour nests the CD8+ and 
FoxP3+ lymphocytes, and not the CD4+ and CD20+ cells, 
were significantly associated with survival, and only in the 
ER/PR positive patients (Fig. 4c, d). High levels of CD8+ or 
FoxP3+ lymphocytes were associated with reduced survival 
in ER/PR positive (p = 0.0013 and p = 0.005 respectively), 
but not ER/PR negative patients. We concluded that TIL 
subtypes were differentially associated with patient survival, 
and that these relationships depended on both intra-tumoural 
location, and hormone receptor status.
High levels of CD20+ TILs at tumour edge are 
associated with better survival
Survival analyses were also performed to assess impacts 
of infiltration at tumour edge, using the three categories of 
infiltration already defined; mild, moderate and heavy. No 
lymphocyte subtypes showed significant impacts on sur-
vival, although higher levels of infiltration with CD20+ TILs 
showed a trend for being associated with improved outcomes 
(p = 0.054). However, this was significant when moderate 
and heavy infiltration groups were combined to allow com-
parison with mild infiltration (high vs low p = 0.02; Fig. 4e). 
Note that infiltration at tumour edge was only assessable in a 
cohort subset (n = 46), and in this context separate analysis 
in ER/PR positive/negative groups was not possible due to 
lack of statistical power.
Discussion
TILs in breast cancer have been studied since the 1950s [22] 
and are now the subject of a vast literature. For the first few 
decades, reports supported the idea that TILs represented 
tumour immune recognition as a host defence mechanism, 
and accordingly their presence was associated with improved 
outcomes [23]. However, this simple story has not stood the 
test of time, with current reports detailing a huge variety of 
positive and negative associations with outcome or treatment 
response, depending on lymphocyte subtype, location within 
the tumour, or molecular subtype of the cases [1, 2, 15, 16]. 
Here, we have encompassed much of this complexity within 
one cohort in an effort to determine whether these factors are 
indeed associated with different conclusions, and therefore, 
that some literature that is superficially conflicting may in 
fact be concordant based on sometimes subtle differences 
in the location of the TILs quantified or the cohort case 
mix. The fact that we, and others, show TILs of different 
subclasses to infiltrate differentially between tumour com-
partments (Fig. 2) and in tumours of different pathological 
features (Fig. 3), supports the proposal that these factors may 
impact on tumour behaviour.
In terms of prognosis, we present some findings that con-
form to the model proposed in the last century with higher 
levels of TILs associated with improved outcomes, but we 
superimpose onto this complexity demonstrating that this is 
only the case for stromally located TILs that are positive for 
CD20 (B cells) or CD4 (helper T cells) and only within ER-
negative cases. This is consistent with a published study in 
which stromal CD20 cells have been associated with longer 
survival in only the triple negative tumours (a majority sub-
set of the ER-negative cases) [24], although this association 
has also been reported as holding irrespective of lympho-
cyte location and ER status [11]. Regarding CD4 cells, our 
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Fig. 4  Tumour infiltrating lymphocytes predict outcome, depend-
ing on subclass, location, and ER/PR status of the cases. Levels of 
lymphocyte staining for CD4, CD20, CD8 or FoxP3 in tumour 
stroma, tumour cell nests or tumour edge were quantified and then 
dichotomised into high and low groups by receiver operator curve 
analyses or, in the case of edge, by combining heavy and moderate 
groups. The influence of levels on cancer survival was assessed using 
Kaplan–Meier survival analyses. a Stromal CD4 in total cohort (left), 
or the ER/PR negative (middle) and ER/PR positive (right) sub-
groups. b Stromal CD20 in ER/PR negatives (left) and ER/PR posi-
tives (right). c Tumour nest CD8 in the ER/PR negatives (left) and 
ER/PR positives (right). d Tumour nest FoxP3 in the ER/PR nega-
tives (left) and ER/PR positives (right). e Tumour edge CD20 in the 
cohort for which edge scores were available (n = 46)
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observation is also in agreement with previous data showing 
the presence of these cells to correlate with longer survival 
specifically in ER-negative cases, although in this study 
lymphocytes were quantified throughout the tumour with-
out analyses of separate compartments [25]. By contrast, we 
demonstrate that tumour nest located lymphocytes that are 
positive for CD8 (cytotoxic T cells) or FoxP3 (regulatory T 
cells) have exactly the opposite correlation with outcome, 
and only within ER-positive cases. There is, again, support 
for this in the literature in the relatively few studies that 
have separately quantified in tumour nest and stromal com-
partments. For example, in an overwhelmingly ER-positive 
cohort, tumour nest but not stromal CD8 cells were shown 
to correlate with reduced survival [26]. Similarly, FoxP3+ T 
cells have been shown to predict poor survival when located 
within the tumour nests but not in stroma that is at least one 
cell away from tumour cells, although this was not broken 
down on ER status [27], and the correlation has also been 
reported specifically in ER-positive but not in ER-negative 
cases, although this study failed to differentiate between 
tumour compartments [28].
A unique aspect of our study is that we examined whether 
levels of different TIL subtypes correlate with their matched 
circulating levels; to the best of our knowledge there are no 
such reports in breast, although we have found one recent 
study including only regulatory T cells in breast [29], and 
some in other cancers [30–32], with a largest cohort of 32. 
This is a key question because it informs our understanding 
of mechanistic influences, local or systemic, that drive accu-
mulation of each TIL subtype in the separate compartments. 
It is also of potential clinical importance since in the event 
of a strong correlation, circulating levels could present an 
attractive minimally-invasive surrogate marker for TILs for 
use in prognostication. We found positive, although rela-
tively weak, correlations between both stromal and tumour 
nest CD8+ cells, but not those at the tumour edge, and cir-
culating CD8+ levels, but no significant correlations for any 
other lymphocyte type. This implies that tumour recruitment 
of B cells, helper T cells, and regulatory T cells is mainly 
governed by local factors irrespective of the systemic lev-
els, whereas a component of recruitment of CD8+ cytotoxic 
cells results simply from reflecting levels available in the 
circulation. The conclusion regarding CD8+ cells is sup-
ported by a similar positive correlation in oral squamous 
cell carcinoma, although in this case CD4+ helper cells also 
correlated significantly [30], but contrasts with no correla-
tion in cancers of the larynx [31] and a significant negative 
correlation in urothelial carcinoma recurrences [32]. Two 
reports comment on the correlation for T regulatory cells, 
both finding positive correlations, in cancers of the larynx 
[31] or in 17 cases of triple-negative breast cancer [29].
Overall, we conclude that TILs are recruited to differ-
ent tumour compartments in the main by differential local 
influences that act with some degree of independence on 
the TIL subtypes. TIL levels reflect different tumour biolo-
gies in terms of their molecular subtype and prognosis. It is 
likely that thorough assessment of TIL subtype, location, 
and tumour molecular subtype will be required for TILs to 
deliver their potential as clinical prognostic or predictive 
markers.
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